CD200 expression in patients with Multiple Myeloma: Another piece of the puzzle

Leukemia Research

Volumn 37, Issue 12, 2013, Pages 1616-1621

  Conticello, Concetta ^a   Giuffrida, Raffaella ^a   Parrinello, Nunziatina ^b   Buccheri, Simona ^a   Adamo, Luana ^a   Sciuto, Maria Rita ^a   Colarossi, Cristina ^a   Aiello, Eleonora ^a   Chiarenza, Annalisa ^b   Romano, Alessandra ^b   Salomone, Edvige ^b   Gulisano, Massimo ^a   Giustolisi, Rosario ^a   Di Raimondo, Francesco ^b  

^a Department of Experimental Oncology   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

CD200; ERK pathway; Immunoregulation; MEK inhibitor; Multiple Myeloma; T cells

Indexed keywords

CD200 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; UO 126;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG TARGETING; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOREGULATION; MIXED LYMPHOCYTE REACTION; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 84888135329     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.08.006     Document Type: Article

References (18)

1. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5(4):263-274.
2. Gorczynski R.M. CD200 and its receptors as targets for immunoregulation. Curr Opin Investig Drugs 2005, 6(5 (May)):483-488.
3. Kretz-Rommel A., Qin F., Dakappagari N., Ravey E.P., McWhirter J., Oltean D., et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 2007, 178(9 (May)):5595-5605.
4. Minas K., Liversidge J. Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal?. Crit Rev Immunol 2006, 26(3):213-230.
5. Moreaux J., Veyrune J.L., Reme T., De V.J., Klein B. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun 2008, 366:117-122.
6. Petermann K.B., Rozenberg G.I., Zedek D., Groben P., McKinnon K., Buehler C., et al. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 2007, 117(12 (December)):3922-3929.
7. Moreaux J., Hose D., Reme T., Jourdan E., Hundemer M., Legouffe E., et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006, 108(13 (December)):4194-4197.
8. Olteanu H., Harrington A.M., Hari P., Kroft S.H. CD200 expression in plasma cell myeloma. Br J Haematol 2011, 153(3 (May)):408-411.
9. Dorfman D.M., Shahsafaei A. CD200 (OX-2 membrane glycoprotein) expression in b cell-derived neoplasms. Am J Clin Pathol 2010, 134(5 (November)):726-733.
10. Tonks A., Hills R., White P., Rosie B., Mills K.I., Burnett A.K., et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007, 21(3 (March)):566-568.
11. Palumbo G.A., Parrinello N., Fargione G., Cardillo K., Chiarenza A., Berretta S., et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res 2009, 33(9 (September)):1212-1216.
12. Conticello C., Giuffrida R., Adamo L., Anastasi G., Martinetti D., Salomone E., et al. NF-κB localization in multiple myeloma plasma cells and mesenchymal cells. Leuk Res 2011, 35(1 (January)):52-60.
13. Kawasaki B.T., Farrar W.L. Cancer stem cells, CD200 and immunoevasion. Trends Immunol 2008, 29(10 (October)):464-468.
14. Alapat D., Coviello-Malle J., Owens R., Qu P., Barlogie B., Shaughnessy J.D., et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol 2012, 137(1 (January)):93-100.
15. Kim K., Kong S.Y., Fulciniti M., Li X., Song W., Nahar S., et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol 2010, 149(4 (May)):537-549.
16. Kretz-Rommel A., Qin F., Dakappagari N., Cofiell R., Faas S.J., Bowdish K.S. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 2008, 180(2 (January)):699-705.
17. Wong K.K., Khatri I., Shaha S., Spaner D.E., Gorczynski R.M. The role of CD200 in immunity to B cell lymphoma. J Leukoc Biol 2010, 88:361-372.
18. McWhirter J.R., Kretz-Rommel A., Saven A., Maruyama T., Potter K.N., Mockridge C.I., et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci U S A 2006, 103(4 (January)):1041-1046.